samedan logo
 
 
 
spacer
home > pmps > summer 2008 > rfid to the rescue
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

RFID to the Rescue

During the development process of new therapeutic approaches, multi-phase clinical research studies (clinical trials) are the last hurdle to overcome. Hence clinical trials represent one of the crucial steps in the development of a new drug. In view of increasing competition, rising cost pressures and, above all, the need to bring new products to market as quickly as possible, the current process of clinical trial supply management harbours inefficiencies, which can be eliminated by innovative RFID-based technologies.

‘TIME TO MARKET’ IS CRUCIAL

The total costs of developing a new drug or treatment up to the point of approval can amount to as much as US$ 1 billion. Typically, a new drug will have been subjected to around 10 years of stringent preclinical testing before entering the first of a total of three clinical trial phases. Nonetheless, according to information published by the FDA in 2004, a new drug has merely an eight per cent chance of achieving final approval and thus being brought to market. One of the reasons for this is the fact that results obtained in animal tests can be applied to humans only to a limited extent: around 90 per cent of substances found to be safe with lab animals fail the test of subsequent clinical trials on humans.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Guido Moosmann is Business Development Director RFID at Schreiner MediPharm, one of the major divisions of Schreiner Group based in Oberschleissheim near Munich, Germany. Guido has extensive academic and industry experience in the field of RFID technologies. He is the author and co-author of various studies and books on source tagging and RFID standards.
spacer
Guido Moosmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Volga-Dnepr’s Cargo Supermarket Spins Healthcare Logistics Across Transatlantic Through A Collaborative Approach

Volga-Dnepr Group continues to support the life-saving uninterrupted supply chains through its dedicated services and Cargo Supermarket offering in partnership with DHL Global Forwarding LS&H sector experts. This time AirBridgeCargo Airlines and CargoLogicAir organized delivery of insulin in a batch of Envirotainer and DoKaSch RAP containers from Milan (Italy) to Chicago (USA).
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement